Literature DB >> 2893084

Multimodal approach to screening for ovarian cancer.

I Jacobs1, I Stabile, J Bridges, P Kemsley, C Reynolds, J Grudzinskas, D Oram.   

Abstract

1010 postmenopausal women were recruited for an ovarian cancer screening programme incorporating serum CA-125 measurement and vaginal examination as initial tests and real-time ultrasonography as a secondary procedure in selected cases. The normal range for serum CA-125 in postmenopausal women was established. The specificity for ovarian cancer of serum CA-125 measurement and vaginal examination were 97.0% and 97.3%, respectively. The combinations of serum CA-125 measurement with ultrasound and vaginal examination with ultrasound achieved specificities of 99.8% and 99.0%, respectively. 100% specificity was achieved by serum CA-125 measurement with vaginal examination and by the combination of all three tests. The findings indicate that no individual screening test has acceptable specificity for ovarian cancer in postmenopausal women. However, the combination of CA-125 measurement with ultrasound did achieve acceptable specificity and offers the most hope of a specific and sensitive method for early detection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893084     DOI: 10.1016/s0140-6736(88)90351-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Screening for ovarian cancer: recommendation statement.

Authors: 
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

3.  Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.

Authors:  Alpa M Nick; Rebecca L Stone; Guillermo Armaiz-Pena; Bulent Ozpolat; Ibrahim Tekedereli; Whitney S Graybill; Charles N Landen; Gabriel Villares; Pablo Vivas-Mejia; Justin Bottsford-Miller; Hye Sun Kim; Ju-Seog Lee; Soo Mi Kim; Keith A Baggerly; Prahlad T Ram; Michael T Deavers; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Natl Cancer Inst       Date:  2011-09-28       Impact factor: 13.506

4.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

5.  Lights and shadows of the tumoral marker CA-125 in ovarian cancer.

Authors:  A Sánchez Muñoz; A González Martín; C Mendiola Fernández
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

6.  [Clinical utility of serous tumoural markers].

Authors:  A Martín Suárez; L Alonso Díaz; I Ordiz Alvarez; J Vázquez; F Vizoso Piñeiro
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

7.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

8.  Transabdominal ultrasound screening for early ovarian cancer.

Authors:  S Campbell; V Bhan; P Royston; M I Whitehead; W P Collins
Journal:  BMJ       Date:  1989-12-02

9.  Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.

Authors:  Etsuko Miyagi; Yasuyo Maruyama; Tae Mogami; Reiko Numazaki; Atsuko Ikeda; Hiroshi Yamamoto; Fumiki Hirahara
Journal:  Int J Clin Oncol       Date:  2016-09-13       Impact factor: 3.402

10.  Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer.

Authors:  Jianghong Li; Cheryl A Sherman-Baust; Miyun Tsai-Turton; Robert E Bristow; Richard B Roden; Patrice J Morin
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.